{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T10:10:01Z","timestamp":1744711801768,"version":"3.40.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-025-05840-4","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T11:39:38Z","timestamp":1743766778000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Novel association of chilblains with inflammatory arthritis- series of three cases and review of literature"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2214-2360","authenticated-orcid":false,"given":"Nilay","family":"Joshi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1822-3635","authenticated-orcid":false,"given":"Salamat","family":"Ullah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6843-6703","authenticated-orcid":false,"given":"Amit","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9979-6066","authenticated-orcid":false,"given":"Shirish","family":"Dubey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"issue":"8","key":"5840_CR1","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, CASPAR Study Group (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54(8):2665\u20132673. https:\/\/doi.org\/10.1002\/art.21972","journal-title":"Arthritis Rheum"},{"issue":"6","key":"5840_CR2","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.2214\/AJR.16.16366","volume":"207","author":"E Smitaman","year":"2016","unstructured":"Smitaman E, Pereira BP, Huang BK et al (2016) Abnormal bone marrow signal intensity in the phalanges of the foot as a manifestation of Raynaud phenomenon: A report of six patients. AJR Am J Roentgenol 207(6):1252\u20131256","journal-title":"AJR Am J Roentgenol"},{"issue":"5","key":"5840_CR3","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1093\/rheumatology\/ket324","volume":"53","author":"S Patel","year":"2014","unstructured":"Patel S (2014) Primary bone marrow oedema syndromes. Rheumatology (Oxford) 53(5):785\u2013792","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"5840_CR4","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1007\/s00256-023-04337-0","volume":"52","author":"LNM da Silva","year":"2023","unstructured":"da Silva LNM, Guimar\u00e3es JB, Link TM et al (2023) Prevalence of phalangeal bone marrow edema on MRI before and during the COVID-19 pandemic and correlation with chilblain skin lesions. Skeletal Radiol 52(9):1721\u20131728","journal-title":"Skeletal Radiol"},{"issue":"2","key":"5840_CR5","doi-asserted-by":"publisher","first-page":"551","DOI":"10.3390\/jcm9020551","volume":"9","author":"SF Baumbach","year":"2020","unstructured":"Baumbach SF, Pfahler V, Bechtold-Dalla Pozza S et al (2020) How we manage bone marrow Edema-An interdisciplinary approach. J Clin Med 9(2):551","journal-title":"J Clin Med"},{"issue":"2","key":"5840_CR6","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3899\/jrheum.090062","volume":"37","author":"E Olech","year":"2010","unstructured":"Olech E, Crues JV 3rd, Yocum DE, Merrill JT (2010) Bone marrow edema is the most specific finding for rheumatoid arthritis (RA) on Noncontrast magnetic resonance imaging of the hands and wrists: a comparison of patients with RA and healthy controls. J Rheumatol 37(2):265\u2013274. https:\/\/doi.org\/10.3899\/jrheum.090062","journal-title":"J Rheumatol"},{"issue":"1","key":"5840_CR7","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13075-019-1824-z","volume":"21","author":"S Ohrndorf","year":"2019","unstructured":"Ohrndorf S, Boer AC, Boeters DM et al (2019) Do musculoskeletal ultrasound and magnetic resonance imaging identify synovitis and tenosynovitis at the same joints and tendons? A comparative study in early inflammatory arthritis and clinically suspect arthralgia. Arthritis Res Ther 21(1):59","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"5840_CR8","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1093\/rheumatology\/keq268","volume":"49","author":"S Chitale","year":"2010","unstructured":"Chitale S, Ciapetti A, Hodgson R et al (2010) Magnetic resonance imaging and musculoskeletal ultrasonography detect and characterize Covert inflammatory arthropathy in systemic sclerosis patients with arthralgia. Rheumatology (Oxford) 49(12):2357\u20132361","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"5840_CR9","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.jaci.2020.08.017","volume":"146","author":"PA Nigrovic","year":"2020","unstructured":"Nigrovic PA, Lee PY, Hoffman HM (2020) Monogenic autoinflammatory disorders: conceptual overview, phenotype, and clinical approach. J Allergy Clin Immunol 146(5):925\u2013937","journal-title":"J Allergy Clin Immunol"},{"key":"5840_CR10","doi-asserted-by":"publisher","first-page":"631329","DOI":"10.3389\/fped.2021.631329","volume":"9","author":"DM d\u2019Angelo","year":"2021","unstructured":"d\u2019Angelo DM, Di Filippo P, Breda L et al (2021) Type I interferonopathies in children: an overview. Front Pediatr 9:631329","journal-title":"Front Pediatr"},{"issue":"1","key":"5840_CR11","doi-asserted-by":"publisher","first-page":"e002864","DOI":"10.1136\/rmdopen-2022-002864","volume":"9","author":"J Rodr\u00edguez-Carrio","year":"2023","unstructured":"Rodr\u00edguez-Carrio J, Burska A, Conaghan PG et al (2023) Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider. RMD Open 9(1):e002864","journal-title":"RMD Open"},{"issue":"3 Pt B","key":"5840_CR12","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.jid.2021.07.189","volume":"142","author":"S Savic","year":"2022","unstructured":"Savic S, Coe J, Laws P, Autoinflammation (2022) Interferonopathies and other autoinflammatory diseases. J Invest Dermatol 142(3 Pt B):781\u2013792","journal-title":"J Invest Dermatol"},{"issue":"6","key":"5840_CR13","doi-asserted-by":"publisher","first-page":"e0128262","DOI":"10.1371\/journal.pone.0128262","volume":"10","author":"M Dolcino","year":"2015","unstructured":"Dolcino M, Ottria A, Barbieri A et al (2015) Gene expression profiling in peripheral blood cells and synovial membranes of patients with psoriatic arthritis. PLoS ONE 10(6):e0128262","journal-title":"PLoS ONE"},{"issue":"4","key":"5840_CR14","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nrrheum.2018.31","volume":"14","author":"TLW Muskardin","year":"2018","unstructured":"Muskardin TLW, Niewold TB (2018) Type I interferon in rheumatic diseases. Nat Rev Rheumatol 14(4):214\u2013228","journal-title":"Nat Rev Rheumatol"},{"key":"5840_CR15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.cytogfr.2021.12.002","volume":"64","author":"H Gu","year":"2022","unstructured":"Gu H, Zhang Y, Zeng W et al (2022) Participation of interferons in psoriatic inflammation. Cytokine Growth Factor Rev 64:12\u201320","journal-title":"Cytokine Growth Factor Rev"},{"key":"5840_CR16","doi-asserted-by":"publisher","first-page":"108513","DOI":"10.1016\/j.clim.2020.108513","volume":"218","author":"H Dai","year":"2020","unstructured":"Dai H, Adamopoulos IE (2020) Psoriatic arthritis under the influence of IFN\u03b3. Clin Immunol 218:108513","journal-title":"Clin Immunol"},{"issue":"12","key":"5840_CR17","doi-asserted-by":"publisher","first-page":"4631","DOI":"10.1093\/rheumatology\/keac231","volume":"61","author":"S Dubey","year":"2022","unstructured":"Dubey S, Joshi N, Stevenson O et al (2022) Chilblains in immune-mediated inflammatory diseases: a review. Rheumatol (Oxford England) 61(12):4631\u20134642","journal-title":"Rheumatol (Oxford England)"},{"issue":"5","key":"5840_CR18","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1177\/1203475421995130","volume":"25","author":"M Pratt","year":"2021","unstructured":"Pratt M, Mahmood F, Kirchhof MG (2021) Pharmacologic treatment of idiopathic chilblains (Pernio): A systematic review. J Cutan Med Surg 25(5):530\u2013542","journal-title":"J Cutan Med Surg"},{"key":"5840_CR19","unstructured":"Etanercept infliximab and adalimumab for the treatment of psoriatic arthritis. National Institute for Health and Care Excellence. https:\/\/www.nice.org.uk\/guidance\/ta199. Last accessed 26th August 2024"},{"key":"5840_CR20","unstructured":"TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis National Institute for Health and Care Excellence. https:\/\/www.nice.org.uk\/guidance\/ta383. Last accessed 26th August 2024"},{"issue":"10","key":"5840_CR21","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1056\/NEJMc2001362","volume":"383","author":"A Vanderver","year":"2020","unstructured":"Vanderver A, Adang L, Gavazzi F et al (2020) Janus kinase Inhibition in the Aicardi-Gouti\u00e8res syndrome. N Eng J Med 383(10):986\u2013989","journal-title":"N Eng J Med"},{"issue":"12","key":"5840_CR22","first-page":"3573","volume":"39","author":"Efficacy","year":"2020","unstructured":"Efficacy (2020) Safety of Upadacitinib in patients with active psoriatic arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 24-week results of the phase 3 SELECT-PsA 2 trial. McInnes IB. Et Al Clin Rheumatol 39(12):3573\u20133583","journal-title":"Et Al Clin Rheumatol"},{"key":"5840_CR23","unstructured":"Upadacitinib for treating moderate rheumatoid arthritis. National Institute for Health and Care Excellence https:\/\/www.nice.org.uk\/guidance\/ta744. Last accessed 26th August 2024."},{"key":"5840_CR24","unstructured":"Upadacitinib for treating severe rheumatoid arthritis. National Institute for Health and Care Excellence https:\/\/www.nice.org.uk\/guidance\/TA665\/chapter\/1-Recommendations. Accessed 16 Dec 2022"},{"key":"5840_CR25","unstructured":"Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs National Institute for Health and Care excellence. https:\/\/www.nice.org.uk\/guidance\/ta768 Last accessed 26th August 2024"},{"issue":"3","key":"5840_CR26","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1912196","volume":"382","author":"EF Morand","year":"2020","unstructured":"Morand EF, Furie R, Tanaka Y et al (2020) Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med 382(3):211\u2013221","journal-title":"N Engl J Med"},{"issue":"2","key":"5840_CR27","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1093\/bjd\/ljad089","volume":"189","author":"LM Carter","year":"2023","unstructured":"Carter LM, Wigston Z, Laws P, Vital EM (2023) Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers. Br J Dermatol 189(2):210\u2013218. https:\/\/doi.org\/10.1093\/bjd\/ljad089","journal-title":"Br J Dermatol"},{"key":"5840_CR28","doi-asserted-by":"publisher","unstructured":"Martins A, L\u00e9 AM, Torres T (2023) Deucravacitinib for the treatment of psoriatic arthritis: the evidence so far. Drugs Context 12:2023-2-7. https:\/\/doi.org\/10.7573\/dic.2023-2-7","DOI":"10.7573\/dic.2023-2-7"},{"key":"5840_CR29","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1136\/annrheumdis-2023-eular.3881","volume":"82","author":"C Arriens","year":"2023","unstructured":"Arriens C, Askanase A, Furie R et al (2023) Design of 2 phase 3, double-blind, placebo-controlled, global trials of Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with active systemic lupus erythematosus. Ann Rheum Dis 82:1463","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"5840_CR30","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.jaci.2021.07.028","volume":"148","author":"YJ Crow","year":"2021","unstructured":"Crow YJ, Neven B, Fr\u00e9mond ML (2021) JAK Inhibition in the type I interferonopathies. J Allergy Clin Immunol 148(4):991\u2013993. https:\/\/doi.org\/10.1016\/j.jaci.2021.07.028","journal-title":"J Allergy Clin Immunol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-025-05840-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-025-05840-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-025-05840-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T09:39:49Z","timestamp":1744709989000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-025-05840-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,2]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["5840"],"URL":"https:\/\/doi.org\/10.1007\/s00296-025-05840-4","relation":{},"ISSN":["1437-160X"],"issn-type":[{"type":"electronic","value":"1437-160X"}],"subject":[],"published":{"date-parts":[[2025,4,2]]},"assertion":[{"value":"27 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all the patients prior to submission.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"None relevant.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}],"article-number":"85"}}